Chemours stock gains after UBS cuts its price target

Chemours shares gained 1.31% to $13.89 despite UBS lowering its price target to $16, while Q2 revenue reached $1.591 billion with a narrowed net loss. Analyst consensus remains Hold with an average 12-month target of $20.10.